Ciara Kennedy, Sorriso Pharmaceuticals CEO
February 27, 2025 05:10 AM ESTUpdated 06:15 AM
R&D

Start­up work­ing on oral an­ti­bod­ies shares ear­ly ul­cer­a­tive col­i­tis da­ta

Max Gelman

Senior Editor

Pri­vate start­up Sor­riso Phar­ma­ceu­ti­cals laid out Phase 1b da­ta at a med­ical con­fer­ence last week­end as part of its ef­fort to bring an oral an­ti­body …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Phar­ma's wins and loss­es in Trump's sprawl­ing ex­ec­u­tive or­der on drug prices

In a blow to its obe­si­ty pipeline, Pfiz­er drops oral drug af­ter liv­er in­jury case

Ex­clu­sive: A small biotech will bring Roche's An­gel­man drug back to life

Eli Lil­ly re­ports first Phase 3 da­ta for oral GLP-1, post­ing a win in di­a­betes

What's Pfiz­er's next move af­ter shelv­ing its oral obe­si­ty drug danuglipron?

sponsored

New York-based part­ner­ship sets the stan­dard for ex­pand­ing clin­i­cal tri­al ac­cess for un­der­served and di­verse ...

A service from the Financial Times